Lyn was a straight shooter but always able to bring others into the fold in a warm and welcoming way. She eased into her board role with CNETS and quickly became a valued, reliable member of the board, advisor, and a caring friend. Many will remember Lyn from her inspiring talk at the CNETS 2019 Patient Conference. Lyn was also a strong patient advocate outside of the neuroendocrine cancer space, sharing her knowledge, experience and common-sense observations among many medical-related forums.
Lyn resigned from the CNETS board earlier this year due to her failing health and very sadly passed away in September. Lyn was a generous volunteer and an incredible advocate for the neuroendocrine community, never afraid to speak up and share her experiences for the benefit of the broader patient population.
Lyn made an immeasurable contribution to our cause and beyond during her two-year tenure on our board of directors. Lyn was a very strong, compassionate, and knowledgeable advocate and an inspiration to anyone she met. Lyn is greatly missed by the NET cancer community, and it is our honour to posthumously present Lyn Gaetz with the 2021 Maureen Coleman Award.[/fusion_text]
Dr. Simron Singh
Dr. Simron Singh is an Associate Professor at the University of Toronto, the Provincial Head, Person-Centered Care, Cancer Care Ontario, and a Medical Oncologist at Sunnybrook Odette Cancer Center/Susan Leslie Clinic for Neuroendocrine Cancers.
Dr. Singh embodies the spirit and passion of the Maureen Coleman Award, devoting his entire career to improving the lives of NET patients and bringing global attention to NETs as a disease that matters. His expertise in health services research and quality improvement has been instrumental in not only improving access to clinical trials, but to use patient-reported data to improve the lives of patients today.
Dr. Singh published one of the first global studies in collaboration with patient stakeholders (INCA) on the Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis. Within this survey, it was identified that diagnosis delays, multiple provider visits, and an unmanaged symptom burden plagued the NET patient experience, and he has since worked tirelessly with CNETS and multiple other stakeholders to improve this. He has been a big advocate of ensuring NET patients are seen by NET experts in Centres of Excellence and has contributed to several guidelines on NET patient management. Locally he has led learning opportunities for community care providers on when and how to refer NET patients to specialty centres, as well provided education on managing NET patients to provide shared care closer to home.
Dr. Singh has worked nationally and internationally to improve access to treatments for NETs, but also to improve the way in which we engage patients to ensure alignment of goals. For example, he led the development of the CommNETs/NANETS guidelines for the diagnosis and management of patients with Lung Neuroendocrine Tumors which brought together three different NET societies and included patient advocates to co-create best practice guidelines for this vulnerable patient group. Dr. Singh also co-chaired the Neuroendocrine Advisory Committee at Cancer Care Ontario to engage patients, NET treaters and government stakeholders to provide access to novel treatments like PRRT and Gallium 68 scans in Ontario.
Dr. Singh is passionate about understanding and improving the NET patient experience, through his commitment to NET clinical research, and his collaboration with key NET patient stakeholders to move the pendulum forward in terms of access to novel treatments.
It is our honour to recognize Dr. Singh’s incredible contribution to our community and present him with the well-deserved 2021 Maureen Coleman Award.